{"id":6574,"date":"2025-12-24T18:01:27","date_gmt":"2025-12-24T18:01:27","guid":{"rendered":"https:\/\/microvibenews.com\/?p=6574"},"modified":"2025-12-24T18:01:27","modified_gmt":"2025-12-24T18:01:27","slug":"agios-pharma-stock-a-buy-after-fda-approves-aqvesme-nasdaqagio","status":"publish","type":"post","link":"https:\/\/microvibenews.com\/?p=6574","title":{"rendered":"Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO)"},"content":{"rendered":"<p><\/p>\n<div data-test-id=\"author-root\">\n<p class=\"mb-12 text-medium-2-r text-share-text-3\">This article was written by<\/p>\n<div class=\"relative mb-12 flex justify-between\">\n<div class=\"flex\">\n<div class=\"flex shrink-0 items-center justify-center relative size-36 rounded-full\" data-test-id=\"user-pic-wrapper\"><img alt=\"\" class=\"text-transparent flex w-full items-center justify-center overflow-hidden text-black-5 rounded-full border border-share-text-2 h-full bg-black-5 dark:bg-black-30\" data-test-id=\"user-pic\" height=\"36\" loading=\"lazy\" src=\"https:\/\/seekingalpha.com\/images\/users_profile\/000\/932\/789\/big_pic.png?io=w72 2x\" width=\"36\"\/><\/div>\n<\/div>\n<p><button data-state-text=\"Following\" aria-label=\"Follow Brendan O'Boyle\" class=\"ihjjQ py-8 px-18 o7ZP8 ml-8 mt-0 shrink-0 self-baseline text-small-b relative inline-flex cursor-pointer select-none items-center whitespace-nowrap break-words transition-colors hover:no-underline motion-reduce:transition-none border-black bg-black text-white hover:bg-black-70 disabled:border-transparent disabled:bg-black-20 dark:border-black-10 dark:bg-black-10 dark:text-black dark:hover:border-black-30 dark:hover:bg-black-30 dark:disabled:bg-black-30 w-auto min-h-28 justify-center border px-12 py-1 text-medium-r rounded-6\" data-test-id=\"follow-button\" type=\"button\"><span class=\"\"><span aria-hidden=\"true\" class=\"wMAFB relative flex justify-center\" data-state-placeholder=\"Following\"><span class=\"absolute\">Follow<\/span><\/span><\/span><\/button><\/p>\n<\/div>\n<div class=\"text-medium-2-r\">\n<div class=\"relative\">\n<div class=\"relative overflow-hidden\" style=\"max-height:100%\">\n<div>\n<p>Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance\/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div data-test-id=\"content-container\">\n<p id=\"a-disclosure\"><b>Analyst\u2019s Disclosure:<\/b><span>I\/we have a beneficial long position in the shares of CRSP either through stock ownership, options, or other derivatives.<\/span><span id=\"top-business-disclosure\"> I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. <\/span><\/p>\n<p>All investment opportunities carry inherent risk, including potential loss of principle. Carefully consider your investment objectives, level of experience and risk appetite before making any investment. The above discussion is a framework for investors (both long and short), to understand the factors that will move the underlying security\u2019s price. It is not a prediction and should not be considered investment advice. The author has a beneficial long position in: CRSP, but plans to monitor AGIO for progress in SCD before taking a position.<\/p>\n<p id=\"a-disclosure-more\"><strong>Seeking Alpha&#8217;s Disclosure:<\/strong> Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.<\/p>\n<\/div>\n<p>#Agios #Pharma #Stock #Buy #FDA #Approves #Aqvesme #NASDAQAGIO<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This article was written by Fo&hellip; <\/p>\n","protected":false},"author":1,"featured_media":6575,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[245],"tags":[5739,5740,5741,152,3885,5742,4148,91],"_links":{"self":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/posts\/6574"}],"collection":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6574"}],"version-history":[{"count":0,"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/posts\/6574\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/media\/6575"}],"wp:attachment":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}